MAPS is currently seeking $9 million for European Medicines Agency (EMA) Phase 3 trials to supplement the data gathered for the FDA, with $897,735 already raised and roughly $8.1 million still to go. We have completed key negotiations with EMA, and we will have an ever more precise estimate of timetables and costs for EMA trials in mid-2019 after completion of our negotiations with each country in the EMA in which we will have a Phase 3 site, and with each site.
In October 2018, MAPS raised nearly $845,000 in new donations and pledges from 607 supporters.
On October 6th, MAPS hosted its annual Breakthrough for Psychedelic Medicine benefit dinner in New York City, raising over $104,000. Over 200 people were in attendance this year to enjoy a beautiful evening of food and conversation around the future of psychedelic medicine.
We extend a special thanks to those who so generously supported MAPS last month:
- Threshold Foundation ($23,000)
- Mary & Robert Haft Foundation ($20,000)
- Anonymous ($150,000)
- Joel Kubby Estate & Laura Parks ($94,500)
- Dick and Patty Simon ($10,000)
- Ethan Ruby ($7,000)
- Michael Auerbach ($5,000)
- Ethan Devine ($3,000)
- Robert Eisenberg ($3,000)
- AmazonSmile Foundation ($2,225)
- Ricardo Baca ($1,200)
- Anonymous ($1,014)
- Robert Anton Patterson ($1,000)
- James Youngblood ($1,000)
- Daniel Finster ($1,000)
Donations under $1,000:
- Total: $29,621
Phase 3 MDMA/PTSD Europe:
- Riverstyx Foundation ($500,000)
Phase 3 Therapy Training:
- Anna Gandelman ($3,000)
- Riverstyx Foundation ($30,000)
- Tyler Norris ($1,000)
- Sir Ivan ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $15 or more. maps.org/donate